David Altshuler, geneticist who helped transform Vertex, to retire next year

Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.

By Ben Fidler • Aug. 5, 2025

Gates Foundation pledges $2.5B to women’s health research

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, obstetric care and sexually transmitted infections, among other areas.

By Delilah Alvarado • Aug. 4, 2025

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Xoma strikes deals to buy struggling biotechs HilleVax, Lava

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the sector’s struggles continue.

By Gwendolyn Wu • Aug. 4, 2025

Regeneron cancer bispecific rejected again; Allogene discloses trial death

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

By BioPharma Dive staff • Aug. 1, 2025

Alnylam reaches new highs on strong sales of closely watched rare disease drug

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results Alnylam’s CEO claimed were “not a flash in the pan.”

By Ben Fidler • July 31, 2025

Venture firm Frazier closes $1.3B fund for early-stage biotech investing

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life sciences companies.

By Gwendolyn Wu • July 31, 2025

Moderna to lay off 10% of workforce in ‘difficult but necessary step’

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the “realities of our business.”

By Delilah Alvarado • July 31, 2025

Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA approvals.

By Ned Pagliarulo • July 30, 2025

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five drugs that no longer fit its plans.

By Ben Fidler • July 29, 2025

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical tests and is building a manufacturing network in support.

By Gwendolyn Wu • July 29, 2025

GenAI and real-world data in pharma: 4 questions to fuel effective insights

To truly unlock the power of RWD, GenAI must go beyond checking a box or staying on trend.

By Niyati Parikh, VP, Product Readiness, Panalgo; Matt Guthrie, Director, HEOR and Medical Affairs, Panalgo • July 28, 2025

Sarepta woes mount as Duchenne gene therapy knocked back in Europe

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could further jeopardize Sarepta’s financial future.

By Ben Fidler • Updated July 25, 2025

A TCG offshoot pulls in $400M for biotech startup creation

TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs it can position for partnerships.

By Gwendolyn Wu • July 24, 2025

Galapagos, having backtracked on split, weighs sale of cell therapy business

A decision to possibly sell the business, which was poised to become the centerpiece of a restructuring plan, represents a shift in strategy by new company leaders.

By Kristin Jensen • July 24, 2025

Rocket lays off staff; Abivax capitalizes on immune drug data

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.

By BioPharma Dive staff • July 24, 2025

Abivax stock soars on trial data for ulcerative colitis drug

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

By Kristin Jensen • July 23, 2025

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

By Ben Fidler • July 23, 2025

Sanofi to acquire vaccine biotech in billion-dollar deal

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV and metapneumovirus.

By Delilah Alvarado • Updated July 22, 2025

Replimune drug rejected by FDA; Omega raises $647M biotech fund

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.

By BioPharma Dive staff • July 22, 2025

Apples to apples: Stelara biosimilars and the fight for market share

How will payers determine which Stelara biosimilar to add to their formularies?

By Samantha Ngan, Associate Manager, Market Research, MMIT and Andrew Rouff, Senior Consultant, Advisory Services, MMIT • July 21, 2025

Bristol Myers’ Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.

By BioPharma Dive staff • July 18, 2025

Sarepta reports patient death in limb-girdle trial, compounding concerns on gene therapy risks

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed gene therapy Elevidys.

By Ben Fidler • Updated July 18, 2025

Biotech startup funding dried up in second quarter, HSBC finds

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast start, according to HSBC.

By Gwendolyn Wu • July 17, 2025

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was essential to ensuring Sarepta's "long-term viability."

By Ben Fidler • Updated July 16, 2025

Hengrui, Kailera say dual-acting obesity shot succeeds in China study

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to begin global late-stage testing.

By Ben Fidler • July 15, 2025